Form 8-K - Current report:
SEC Accession No. 0000950170-25-036264
Filing Date
2025-03-10
Accepted
2025-03-10 16:07:40
Documents
13
Period of Report
2025-03-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K engn-20250310.htm   iXBRL 8-K 51604
2 EX-99.1 engn-ex99_1.htm EX-99.1 98574
3 GRAPHIC img7790613_0.jpg GRAPHIC 13126
  Complete submission text file 0000950170-25-036264.txt   338770

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT engn-20250310.xsd EX-101.SCH 55618
15 EXTRACTED XBRL INSTANCE DOCUMENT engn-20250310_htm.xml XML 6503
Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41854 | Film No.: 25723715
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)